Aromatase inhibitors (AIs) have been linked to increased atrial fibrillation(AF) risk due to estrogen depletion however tamoxifen's effect on AF remains conflicting.
This study investigates the risk of AF associated with AI use compared to tamoxifen in breast cancer patients.
